



THE CANADIAN CANCER
RESEARCH **CONFERENCE**

LA **CONFÉRENCE** CANADIENNE
SUR LA RECHERCHE SUR LE CANCER



IN-PERSON PROGRAM PROGRAMME DE LA CONFÉRENCE EN PERSONNE

November 12 - 14, 2023

Halifax, NS

12 au 14 novembre 2023

Halifax, NS

ccra-acrc.ca/conference

CONFERENCE OVERVIEW – In Person

Sunday, November 12, 2023					
8:00 am	Breakfast				
9:00 am	Welcome Remarks				
10:30 am	Plenary Session – Liquid Biopsies				
12:00 pm	Lunch and Poster Exhibit Session				
1:30 pm	Lightning Sessions				
	Bioinformatics, Big Data, AI and Technology	Survivorship	Immunotherapy	Cancer Clinical Research and Trials	Health Services Research, Health Economics, and Implementation Science
2:00 pm	Transition				
2:10 pm	Concurrent Sessions				
	Health Equity	Innovations in Clinical Trials	Pediatric Cancer	Advances in Cancer Immunotherapy	WORKSHOP – DEI in Research Funding and Diversity in Science
3:40 pm	Break				
4:10 pm	Plenary Session – AI Across the Research Spectrum				
Monday, November 13, 2023					
8:00 am	Breakfast				
9:00 am	Concurrent Sessions				
	Improving the Cancer Journey of First Nations, Inuit and Métis	Enhancing Palliative, End-of-Life, and Survivorship Experiences	Metastasis	Cancer Research from Atlantic Canada	WORKSHOP – AI Tools and Methods
10:30 am	Transition				
10:40 am	Lightning Sessions				
	Metastasis	Screening, Early Detection, Diagnosis and Prognosis	Precision Medicine and Biomarkers	Health Disparities and Equity	Pediatric Cancer
11:10 am	Break				
11:40 am	Concurrent Sessions				
	Adolescent and Young Adult Cancer	Tumour Microenvironment	Respecting Partnerships, Governance and Information for change in First Nations, Inuit and Métis cancer care	Crises Affecting Healthcare	CanPath WORKSHOP – Health Services and Policy Research
1:10 pm	Lunch and Poster Exhibit Session				
2:40 pm	Plenary Session – Clinical Innovations in the Real World				
4:10 pm	Break				
4:40 pm	Concurrent Sessions				
	Microbiome	Advances in Cancer Biology	Honoring Culture, Traditions and Language of First Nations, Inuit and Métis	Treatment Resistance	WORKSHOP – Patient Engagement
Tuesday, November 14, 2023					
8:00 am	Breakfast				
9:00 am	Concurrent Sessions				
	Cancer Prevention	Advances in Cancer Treatments	Supporting First Nations, Inuit and Métis Cancer Strategies through Research	Canada-Wide Consortia and Platforms	Multi-omics and Epigenetics
10:30 am	Transition				
10:40 am	Lightning Sessions				
	Metabolism	Patient Experience and Advocacy	Drug Discovery, Design, Delivery and Resistance	Genetics and Epigenetics	Cancer Risk and Primary Prevention
11:10 am	Break				
11:40 am	Plenary Session – Environment and Cancer				
1:10 pm	Closing Remarks				

*Scientific Program subject to change

APERÇU DU PROGRAMME – En Personne

Dimanche 12 novembre 2023

8 h	Déjeuner				
9 h	Mot de bienvenue				
10 h 30	Séance plénière – Les biopsies liquides				
12 h	Dîner et séance de présentations par affiches et d'exposition				
	Séances éclair				
13 h 30	La bio-informatique, les mégadonnées, l'IA et la technologie	La survie	L'immunothérapie	La recherche et les essais cliniques sur le cancer	La recherche sur les services de santé, l'économie de la santé et la science de la mise en œuvre
14 hr	Transition				
	Séances simultanées				
14 h 10	L'équité en santé	Les innovations dans les essais cliniques	Les cancers pédiatriques	Progrès accomplis dans l'immunothérapie contre le cancer	ATELIER – L'EDI dans le financement de la recherche et la diversité en sciences
15 h 40	Pause				
16 h 10	Séance plénière – L'IA dans tous les domaines de la recherche				

Lundi 13 novembre 2023

8 hr	Déjeuner						
	Séances simultanées						
9 hr	Améliorer le parcours face au cancer des Premières Nations, des Inuits et des Métis	Améliorer les expériences des soins palliatifs, des soins de fin de vie et de la survie	Les métastases	Recherches sur le cancer provenant du Canada atlantique		ATELIER – Méthodes et outils liés à l'IA	
10 h 30	Transition						
	Séances éclair						
10 h 40	Les métastases	Le dépistage, la détection précoce, le diagnostic et le pronostic	La médecine de précision et les biomarqueurs	Les disparités et l'équité en matière de santé		Les cancers pédiatriques	
11 h 10	Pause						
	Séances simultanées						
11 h 40	Le cancer chez les adolescents et les jeunes adultes	Le micro-environnement tumoral	Respecter les partenariats, la gouvernance et l'information en faveur du changement dans les soins contre le cancer offerts aux Premières Nations, aux Inuits et aux Métis		Les crises touchant les soins de santé	CanPath	ATELIER – La recherche sur les services et les politiques de santé
13 h 10	Dîner et séance de présentations par affiches et d'exposition						
14 h 40	Séance plénière – Les innovations cliniques dans le monde réel						
16 h 10	Pause						
	Séances simultanées						
16 h 40	Le microbiome	Progrès accomplis dans la biologie du cancer	Respecter la culture, les traditions et les langues des Premières Nations, des Inuits et des Métis		La résistance au traitement	ATELIER – La participation des patients	

Mardi 14 novembre 2023

8 h	Déjeuner				
	Séances simultanées				
9 h	La prévention du cancer	Progrès accomplis dans les traitements contre le cancer	Appuyer les stratégies de lutte contre le cancer chez les Premières Nations, les Inuits et les Métis grâce à la recherche	Plateformes et consortiums pancanadiens	La multiomique et l'épigénétique
10 h 30	Transition				
	Séances éclair				
10 h 40	Le métabolisme	L'expérience des patients et la défense de leurs intérêts	La découverte, la conception et l'administration des médicaments, et la résistance à ceux-ci	La génétique et l'épigénétique	Le risque de cancer et la prévention primaire
11 h 10	Pause				
11 h 40	Séance plénière – L'environnement et le cancer				
13 h 10	Mot de la fin				

* Programme sujet à changement

SUNDAY, NOVEMBER 12, 2023

8:00 am Breakfast	
9:00 am Welcome Remarks	
10:30 am Plenary Session – Liquid Biopsies	
Chairs:	
Dr. Sherri Christian Memorial University of Newfoundland, Beatrice Hunter Cancer Research Institute, Marathon of Hope Cancer Centres, Terry Fox Research Institute Ms. Melissa Coombs Patient Partner Dr. Natasha Leighl Princess Margaret Cancer Centre, University of Toronto Dr. Rodney Ouellette Atlantic Cancer Research Institute Dr. Trevor Pugh Princess Margaret Cancer Centre, University of Toronto	
12:00 pm Lunch and Poster and Exhibit Session	
1:30 pm LIGHTNING SESSIONS	
Bioinformatics, Big Data, AI and Technology	
Developing the pan-Canadian Cancer Data Strategy (cancer data strategy) to guide cancer data improvements and implementation efforts	Ms. Natalie Fitzgerald Canadian Partnership Against Cancer
ARS2 Association with subnuclear Paraspeckles: Implications for Hepatocellular Carcinoma Progression and Drug Resistance	Dr. Gobi Thillainadesan Sunnybrook Research Institute
Survivorship	
Virtually Supervised Exercise for People with Advanced Lung Cancer: Feasibility and Physical Function Results	Dr. Kristin Campbell University of British Columbia
Missed Opportunities in Supporting Informal Cancer Caregiver (and Patient) Health	Mr. Thomas Christensen Dalhousie University
Development of a polygenic score to predict cisplatin-induced ototoxicity	Dr. Britt Drogemoller University of Manitoba
Adjuvant Treatment in High-Grade Serous Endometrial Carcinoma: A Comprehensive Institutional Review	Dr. Sedighe Esmaeilzade McGill University Health Center
Finding Intimacy Without Sex: Exploring the impact of lost intimacy and sexual function after cancer	Ms. Cecile Proctor University of New Brunswick

Immunotherapy

Combination immunotherapy with Smac mimetics potentiate cytokine-induced death of tumor cells

Dr. Shawn Beug
CHEO Research Institute

Exploring immune evasion in breast cancer using novel models of acquired resistance to PD-1/PD-L1 blockade

Dr. Kabir Khan
Sunnybrook Research Institute, University of Toronto

Investigating VSV-based Oncolytic Virus to Overcome ICI-resistant Melanomas

Miss. Tiffany Lin
Goodman Cancer Institute, McGill University

Preclinical Mathematical Models for a Combined Treatment of Chemotherapy and Immunotherapy of Glioblastomas and Optimization of Advanced Treatments

Ms. Blanche Mongeon
Université de Montréal

The long, not short, of it: dual approaches for long-dsRNA based breast cancer therapies

Dr. Sarah Poynter
Wilfrid Laurier University

Cancer Clinical Research and Trials

The untapped therapeutic potential of cholesterol-lowering drugs in solid tumors: the case of a cholesterol embargo on top of standard therapy in advanced pancreatic cancer NCT04862260

Dr. Anne Gangloff
Laval University

BOLD-100-001: A Phase 1b/2a Study of BOLD-100 in Combination with FOLFOX Chemotherapy in Patients with Pre-Treated Advanced Gastrointestinal Cancers: Interim Safety Results

Mr. Michael Snow
Bold Therapeutics, Inc.

Health Services Research, Health Economics, and Implementation Science

Lymphoma Diagnosis Pathway Implementation in Alberta

Mr. Tim Buckland
Alberta Health Services

Pathways to cancer care after a suspected cancer diagnosis in the emergency department: A survey of emergency physicians across Ontario

Dr. Keerat Grewal
Sinai Health

Estimating Cancer Diagnostic Interval Using Deep Learning Method based on Population-based Real-world Health Data

Dr. Yuan Xu
University of Calgary

The Cost of Cancer: A Societal View

Ms. Roxanne Garaszczuk
Canadian Partnership Against Cancer

2:00 pm

Transition

2:10 pm

CONCURRENT SESSIONS

Health Equity

Chair:

Dr. David Busolo
University of New Brunswick, Faculty of Nursing, Moncton Campus, Beatrice Hunter Cancer Research Institute

Dr. Mandana Vahabi
Toronto Metropolitan University

Exploring primary care provider barriers and enablers to implementation of cancer screening with patients experiencing marginalization

Dr. Arlinda Ruco
St. Francis Xavier University

Disparities In Clinical Trial Enrolment At A Canadian Comprehensive Cancer Centre: A Fifteen-Year Retrospective Study

Dr. Gilla Shapiro
Princess Margaret Cancer Centre

Cancer incidence in people with intellectual or developmental disabilities: Two population-based retrospective cohort studies in Manitoba and Ontario, Canada

Dr. Alyson Mahar
Queen's University

Innovations in Clinical Trials

Chair:

Dr. Wendy Parulekar

Canadian Cancer Trials Group, Queen's University

Dr. PJ Devereaux

McMaster University

Cost-Effectiveness Analysis of the Prostate Cancer Patient Empowerment Program (PC-PEP)

Ms. Alexandra Nuyens

Dalhousie University

A phase IIb randomized placebo-controlled trial testing a long-chain omega-3 fatty acid MAG-EPA dietary supplement on prostate cancer aggressiveness

Dr. Karine Robitaille

CHU de Québec, Université Laval Research Center

Pediatric Cancer

Chair:

Dr. Rebecca Deyell

Children's and Women's Health Centre of British Columbia

Dr. Rebecca Deyell

Children's and Women's Health Centre of British Columbia

Large scale drug screens of human engineered acute leukemias and genetically matched patients

Dr. Brian Wilhelm

Université de Montréal

Defining and measuring the value of genetic testing from patients' perspectives: Developing the Patient-reported Genetic testing Utility InDEx (P-GUIDE) for oncology

Dr. Robin Hayeems

The Hospital for Sick Children

Advances in Cancer Immunotherapy

Chair:

Dr. Tak Wah Mak

University of Toronto, Princess Margaret Cancer Centre

Dr. Tak Wah Mak

University of Toronto, Princess Margaret Cancer Centre

Investigating STING activation as a translational immunotherapy for soft tissue sarcomas

Ms. Karys Hildebrand

University of Calgary

WORKSHOP – DEI in Research Funding and Diversity in Science

3:40 pm

Break

4:10 pm

Plenary Session – AI Across the Research Spectrum

Chairs:

Dr. Ali Bashashati

University of British Columbia, Vancouver Coastal Health Research Institute

Dr. Rosilene Kraft

Patient Partner

Dr. Manisha Bahl

Mass General Research Institute, Harvard University

Dr. John Lewis

Faculty of Medicine & Dentistry, University of Alberta

Dr. Muhammad Mamdani

Unity Health, St. Michael's Hospital, University of Toronto

8:00 am	
Breakfast	
9:00 am	
CONCURRENT SESSIONS	
Improving the Cancer Journey of First Nations, Inuit and Métis	
Enhancing Palliative, End-of-Life, and Survivorship Experiences	
Chair:	
Dr. Harvey Chochinov University of Manitoba	Dr. Harvey Chochinov University of Manitoba
	Dr. Mathieos Beylanih University of British Columbia
Metastasis	
Chair:	
Dr. Michael J. Monument Department of Surgery, University of Calgary	Dr. Alison Allan London Health Science Centre, Western University
From molecular mechanism to drug candidate, how we stop the vicious cycle of prolactin-accelerated breast cancer bone metastasis	Dr. Carrie Shemanko University of Calgary
Cancer Research from Atlantic Canada	
Chair:	
Dr. Jeannette Boudreau Dalhousie University, Beatrice Hunter Cancer Research Institute	Dr. David Busolo University of New Brunswick
Improving access to cancer screening is a collaborative endeavour: Perspectives of adult immigrants and refugees in New Brunswick	Dr. Parinaz Nasri Université de Moncton
Investigating the Translational Potential of circPAX5 in B Cancer cells	
WORKSHOP – AI Tools and Methods	
Lead:	
Dr. Shirin Abbasinejad Enger McGill University	
Dr. Parsa Bagherzadeh McGill University	
Ms. Yujing Zou McGill University	
10:30 am	
Transition	

Metastasis

Investigation of roles of DNA methylation inhibition and STING agonist in the treatment of metastatic triple-negative breast cancer

Dr. Sofiane Berrazouane
Lady Davis Institute, McGill University

Exploring a link among protein synthesis, mitochondrial dysfunction, and epithelial-to-mesenchymal transition

Dr. Stephen Lewis
Atlantic Cancer Research Institute

Counterbalance between Wnt/Ā-catenin and ATF2-dependent signalling pathways drives cancer cell invasion and intravasation

Dr. Konstantin Stoletov
University of Alberta

Screening, Early Detection, Diagnosis and Prognosis

DNA Organization Measurements from All the Individual Cells Within Tissue can be Highly Predictive of Cancer Cell Aggressiveness

Dr. Calum MacAulay
BC Cancer

Is Canada prepared for Primary HPV-testing in Cervical Cancer Screening? A national study of the Knowledge, Attitudes, and Beliefs of Under and Adequately Screened Canadians

Dr. Samara Perez
McGill University Health Center

Making Progress in Cancer Control: The Number of Cancer Deaths Avoided in Canada

Dr. Matt Warkentin
University of Calgary

Precision Medicine and Biomarkers

Tumor copy number alterations burden as a predictor for resistance to immune checkpoint blockade across different cancer types

Dr. Karama Asleh
Atlantic Cancer Research Institute

True bench-to-bedside science: An international pilot study modeling hard-to-cure pediatric cancers to prioritize therapeutic intervention

Miss Nadine Azzam
Children's Hospital of Eastern Ontario Research Institute

Exploring a novel triple therapy in hard-to-treat melanomas

Mr. Feiyang Cai
McGill University

Nanopore sequencing of advanced cancers identifies haplotype specific promoter methylation associated with clinically relevant HRD phenotype

Dr. Veronika Cizmok
Canada's Michael Smith Genome Sciences Centre at BC Cancer

Monitoring Epithelial Cell Subtypes in Whole Blood RNA of Prostate Cancer Patients: A Step Towards Precision Oncology

Miss Seta Derderian
RI-MUHC

Orthogonal methods independently quantify protein expression patterns associated with AKT inhibitor response in breast cancer cell lines and patient tumours

Constance Sobsey
McGill University

Health Disparities and Equity

Patient-physician sex concordance and real-world disparities in cancer treatment practices and outcomes

Mr. Philip Ding
University of Alberta

Through the Lens of Health Equity: Organizational Barriers to Accessing Cancer Care for People who are Highly Marginalized

Dr. Tara Horrill
University of Manitoba

Interventions designed to increase the uptake of lung cancer screening: an equity-oriented scoping review

Dr. Ambreen Sayani
Women's College Hospital

Advancing health equity within the pan-Canadian Cancer Data Strategy

Mrs. Kim Tran
Canadian Partnership Against Cancer

Identifying best practices for engaging First Nations, Inuit, and Métis stakeholders in Patient and Family Advisory Committees

Ms. Alexandria McRorie
University of Calgary

Pediatric Cancer

Impact of Early Phase Study Enrollment for Pediatric Oncology Patients on Symptom Burden and Quality of Life: Feasibility

Dr. Lesleigh S Abbott
CHEO

Alternative Polyadenylation in Noradrenergic to Mesenchymal Transition in Neuroblastoma

Ms. Rhea Ahluwalia
University of Toronto

Defining the cellular and molecular characteristics of relapsing Wilms Tumors using single-cell genomics

Dr. Tobias Karakach
Dalhousie University

CBFA2T3-GLIS2-dependent pediatric acute megakaryoblastic leukemia is driven by GLIS2 and sensitive to Navitoclax

Prof. Frederick A. Mallette
Université de Montréal, Maisonneuve-Rosemont Hospital Research Center

Exploring the Possible: 3CTN-C17 Initiatives Used as Incentives to Overcome Barriers to Clinical Trial Access for Pediatric Cancer Patients

Mr. James Schoales
Canadian Cancer Clinical Trials Network (3CTN)

Ms. Kathy Brodeur-Robb
C17 Council

11:10 am

Break

11:40 am

CONCURRENT SESSIONS

Adolescent and Young Adult Cancer

Chair:

Dr. Uri Tabori
The Hospital for Sick Children

Sponsored by:



Children's Cancer & Blood Disorders



Garron Family Cancer Centre

Dr. Uri Tabori
The Hospital for Sick Children

Developing a machine learning classifier for the diagnosis of Li-Fraumeni Syndrome

Ms. Brianne Laverty
The Hospital for Sick Children

Tumour Microenvironment

Chair:

Dr. J. Patrick Murphy
Department of Biology, University of Prince Edward Island, Department of Pathology, University of Prince Edward Island, Beatrice Hunter Cancer Research Institute

Prognosis and chemoresistance in ovarian cancer: the role of immune marker expression

Dr. Arvind Mer
University of Ottawa

Respecting Partnerships, Governance and Information for change in First Nations, Inuit and Métis cancer care

Crises Affecting Healthcare

Chair:

Dr. Robin Urquhart
Dalhousie University, Atlantic Partnership for Tomorrow's Health, Beatrice Hunter Cancer Research Institute, Nova Scotia Health Authority

Dr. Andrew Boozary
Gattuso Centre for Social Medicine, University Health Network, University of Toronto

Dr. Craig Earle
Canadian Partnership Against Cancer

Red River Métis' barriers to access and health equities throughout a cancer journey: a qualitative study

Ms. Chantal Perchotte
Manitoba Métis Federation

CanPath

Chair:

Dr. Philip Awadalla

Ontario Institute for Cancer Research, University of Toronto, Ontario Health Study, CanPath

Risk factors for early-onset colorectal cancer: An analysis of Canadian prospective cohort studies

Dr. Dylan O'Sullivan

Alberta Health Services, University of Calgary

Changes in breast and cervical cancer screening during the COVID-19 pandemic: findings from Alberta's Tomorrow Project

Dr. Sara Nejatnamini

Alberta Health Services

WORKSHOP – Health Services and Policy Research

1:10 pm

Lunch and Poster and Exhibit Session

2:40 pm

Plenary Session – Clinical Innovations in the Real World

Chairs:

Dr. Sachin Katyal

University of Manitoba, CancerCare Manitoba

Ms. Ruth Ackerman

Patient Partner

Dr. June Carroll

Faculty of Medicine, University of Toronto, Granovsky Gluskin Family Medicine Centre, Sinai Health

Dr. Tony Reiman

Atlantic Cancer Research Institute, Beatrice Hunter Cancer Research Institute, Dalhousie University, University of New Brunswick

Dr. Sheila Singh

Cancer Research Centre, McMaster University

4:10 pm

Break

4:40 pm

CONCURRENT SESSIONS

Microbiome

Chair:

Dr. Bertrand Routy

CHUM / CRCHUM

Dr. Bertrand Routy

CHUM / CRCHUM

Dr. Robyn Wright

Dalhousie University

Advances in Cancer Biology

Chair:

Dr. Paola Marcato

Department of Pathology, Dalhousie University

Genome-Wide CRISPR Cas9 Screen Reveals a PARG - PTEN - Dependent Vulnerability in Melanoma

Mr. Emmanuel Asante

McGill University

Improving the cancer survivorship narrative by implanting artificial Intelligence along the health care continuum

Dr. Paola Marignani

Dalhousie University

Honoring Culture, Traditions and Language of First Nations, Inuit and Métis

Treatment Resistance

Chair:

Dr. Franco Vizeacoumar

Saskatchewan Cancer Agency, University of Saskatchewan

Developing combination therapies for telomerase-overexpressing clear cell carcinoma of the ovaries

Identifying cell cycle mediators as essential therapeutic vulnerabilities in cancers with non-V600 BRAF mutations

Bintrafusp alfa improves survival in ovarian cancer models by promoting T effector memory responses

Cytidine deaminases APOBEC3C and APOBEC3D promote DNA replication stress resistance in pancreatic cancer cells

Mr. Vincent Maranda

University of Saskatchewan

Dr. Melody Riaud

Lady Davis Institute

Dr. Andrew Craig

Queen's University

Dr. Grant Brown

University of Toronto

WORKSHOP – Patient Engagement

PRELIMINARY

Cancer Prevention

Chair:

Dr. Rachel Murphy
BC Cancer Research Centre, University of British Columbia

Exploring the Etiology of Rare Cancers Using a Large Occupational Cohort

The effectiveness and cost-effectiveness of population-level policies to reduce alcohol use: a systematic umbrella review

Dr. Rachel Murphy
BC Cancer Research Centre, University of British Columbia

Dr. Paul Demers
Occupational Cancer Research Centre, Ontario Health

Ms. Umama Abbas
University of Western Ontario

Advances in Cancer Treatments

Chair:

Dr. Sachin Katyal
University of Manitoba, CancerCare Manitoba

EZH2 inhibition circumvents PRAME-mediated retinoid resistance in keratinocyte carcinomas

Mr. Brandon Ramchatesingh
McGill University

Supporting First Nations, Inuit and Métis Cancer Strategies through Research

Canada-Wide Consortia and Platforms

Chair:

Dr. Sherri Christian
Memorial University of Newfoundland, Beatrice Hunter Cancer Research Institute, Marathon of Hope Cancer Centres, Terry Fox Research Institute

Dr. Christine Williams
Ontario Institute for Cancer Research, Canadian Pediatric Cancer Consortium

Dr. Philip Awadalla
Ontario Institute for Cancer Research, University of Toronto, Ontario Health Study, CanPath

Stephanie Grover
Terry Fox Research Institute, PROFYLE

Dr. Isabel Serrano
Terry Fox Research Institute, Marathon of Hope Cancer Centres Network

Multi-omics and Epigenetics

Chair:

Dr. Touati Benoukraf
Memorial University of Newfoundland

Dr. Touati Benoukraf
Memorial University of Newfoundland

Metabolism

XP01/CRM1 inhibition modulates autophagy and protein metabolism in cancer cells

Miss Aziliz Duverger
Université de Moncton

Delineating and targeting a novel metabolism-based post-translational mechanism regulating the abundance of the 'undruggable' oncoprotein c-MYC in medulloblastoma

Emma Martell
University of Manitoba

The secret life of a Krebs Cycle enzyme in aggressive cancers and optic neuropathies

Dr. Michael Moran
Hospital for Sick Children, University of Toronto

Patient Experience and Advocacy

Mental Health Among People Living With and Beyond Colorectal Cancer: A Patient-Oriented Constructivist Grounded Theory

Dr. Vicki Cheng
University of British Columbia

The Rethinking Clinical Trials (REaCT) program: transforming pragmatic, practice-changing, patient-centred research across Canada

Dr. Mark Clemons
The Ottawa Hospital Research Institute

Ethical issues experienced in relationships between patients and other team members developing a strategy for meaningful patient engagement in cancer research funding

Dr. Jenny Leese
University of Ottawa

Co-creation of a patient engagement strategy in cancer research funding

Ms. Suzanne Bays
Canadian Cancer Society

Mr. Donald Wood
Canadian Cancer Society

Drug Discovery, Design, Delivery and Resistance

Spatiotemporal modelling of chemoresistance evolution in breast tumors uncovers key dependencies on SLC38A7 and SLC46A1

Dr. Yannick Audet-Delage
University of Ottawa

Utilization of high-content imaging and bioactivity assays for drug screening of metallotherapeutic anticancer agents

Mr. Brian Park
Bold Therapeutics

Genetics and Epigenetics

A systematic approach to studying the effect of cancer histone mutations

Dr. Maria Aristizabal
Queen's University

EZHIP, a new oncogene in osteosarcoma

Dr. Geoffroy Danieau
Research Institute of the McGill University Health Centre

Understanding the Translational Landscape of High-Risk Basal Cell Carcinoma

Miss Sarah Ghezelbash
Lady Davis Institute, McGill University

Deciphering the role of epigenetic combination therapies in ovarian cancer

Mr. Marios Langke
McGill University

Association between sleep characteristics and cancer survival: a Mendelian randomization study

Dr. Lin Yang
Alberta Health Services

Cancer Risk and Primary Prevention

The Nova Scotia Community Cancer Matrix (NS-Matrix): using small-area mapping of preventable cancers to inform and strengthen cancer prevention interventions

Dr. Nathalie Saint-Jacques
Nova Scotia Health

Association between traffic-related air pollution and breast cancer risk in post-menopausal women in Alberta's Tomorrow Project

Ms. Mohadeseh Ahmadi
University of British Columbia

Oral co-infection with multiple alpha-human papillomavirus and head and neck cancer risk

Mary Amure
McGill University

A "Sex Gap" in occupational lung cancer? Exploring sex-differences in lung cancer risk among Ontario workers

Dr. Jevana Sritharan
Ontario Health

11:40 am

Plenary Session – Environment and Cancer

Chairs:

Dr. Robin Urquhart

Dalhousie University, Atlantic Partnership for Tomorrow's Health, Beatrice Hunter Cancer Research Institute, Nova Scotia Health Authority

Dr. Don Desserud

Patient Partner

Dr. Aaron Goodarzi

Cumming School of Medicine, University of Calgary

Dr. Fiona Miller

Centre for Sustainable Health Systems, Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto

Ms. Carol Crowe

Creative Fire

1:10 pm

Closing Remarks

***Scientific Program subject to change**